| Doped zinc oxide nanoparticles: synthesis, characterization and potential use in nanomedicine M Carofiglio, S Barui, V Cauda, M Laurenti Applied Sciences 10 (15), 5194, 2020 | 212 | 2020 |
| Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer J Cullis, D Siolas, A Avanzi, S Barui, A Maitra, D Bar-Sagi Cancer immunology research 5 (3), 182-190, 2017 | 155 | 2017 |
| Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature S Barui, S Saha, G Mondal, S Haseena, A Chaudhuri Biomaterials 35 (5), 1643-1656, 2014 | 151 | 2014 |
| Multimodal decorations of mesoporous silica nanoparticles for improved cancer therapy S Barui, V Cauda Pharmaceutics 12 (6), 527, 2020 | 60 | 2020 |
| Tumor growth inhibition through targeting liposomally bound curcumin to tumor vasculature G Mondal, S Barui, S Saha, A Chaudhuri Journal of Controlled Release 172 (3), 832-840, 2013 | 56 | 2013 |
| The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor G Mondal, S Barui, A Chaudhuri Biomaterials 34 (26), 6249-6260, 2013 | 54 | 2013 |
| Iron-doped ZnO nanoparticles as multifunctional nanoplatforms for theranostics M Carofiglio, M Laurenti, V Vighetto, L Racca, S Barui, N Garino, ... Nanomaterials 11 (10), 2628, 2021 | 43 | 2021 |
| Facile chemical synthesis of doped ZnO nanocrystals exploiting oleic acid S Barui, R Gerbaldo, N Garino, R Brescia, F Laviano, V Cauda Nanomaterials 10 (6), 1150, 2020 | 27 | 2020 |
| Systemic codelivery of a homoserine derived ceramide analogue and curcumin to tumor vasculature inhibits mouse tumor growth S Barui, S Saha, V Yakati, A Chaudhuri Molecular Pharmaceutics 13 (2), 404-419, 2016 | 25 | 2016 |
| Paradoxical role of AT-rich interactive domain 1A in restraining pancreatic carcinogenesis S Ferri-Borgogno, S Barui, AM McGee, T Griffiths, PK Singh, CG Piett, ... Cancers 12 (9), 2695, 2020 | 19 | 2020 |
| Development of doped ZnO-based biomimicking and tumor-targeted nanotheranostics to improve pancreatic cancer treatment S Barui, NM Percivalle, M Conte, B Dumontel, L Racca, M Carofiglio, ... Cancer Nanotechnology 13 (1), 37, 2022 | 11 | 2022 |
| Synthesis and characterization of quinoline-3-carboxamide derivatives as inhibitors of the ATM kinase S Ravi, S Barui, S Kirubakaran, P Duhan, K Bhowmik Current Topics in Medicinal Chemistry 20 (23), 2070-2079, 2020 | 7 | 2020 |
| Macropinocytosis of Nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol. Res. 2017; 5: 182–190. doi: 10.1158/2326-6066 J Cullis, D Siolas, A Avanzi, S Barui, A Maitra, D Bar-Sagi CIR-16-0125.[Europe PMC free article][Abstract][CrossRef][Academic Search], 0 | 6 | |
| Dual drug loaded nanotheranostic platforms as a novel synergistic approach to improve pancreatic cancer treatment S Barui, M Conte, NM Percivalle, RMG Montero, L Racca, M Allione, ... Particle & Particle Systems Characterization 40 (4), 2200138, 2023 | 3 | 2023 |
| In vivo targeting of a tumor-antigen encoded DNA vaccine to dendritic cells in combination with tumor-selective chemotherapy eradicates established mouse melanoma S Barui, S Saha, Y Venu, GK Moku, A Chaudhuri Biomaterials Science 11 (18), 6135-6148, 2023 | 3 | 2023 |
| Development of multifunctional iron-doped ZnO nanoparticles addressing pancreatic cancer cells M Carofiglio, M Laurenti, L Racca, S Barui, N Garino, V Cauda CANCERTO-NANOSCIENCE IN CANCER IMMUNOTHERAPY, 57, 2023 | | 2023 |
| Targeting the Ataxia Telangiectasia Mutated (ATM) kinase for alleviating cancer S Ravi, S Barui, S Kirubakaran | | 2019 |
| Targeting the DDR pathway: the pathway to success against the Emperor of Maladies S Ravi, S Barui, S Kirubakaran | | 2019 |
| Targeting the DNA damage and repair pathway a combinatorial approach towards cancer treatment S Ravi, S Barui, S Kirubakaran | | 2019 |
| Development of novel quinoline based small molecules for targeting the kinases of the DNA damage and repair pathway S Ravi, S Barui, S Kirubakaran | | 2018 |